Last reviewed · How we verify
Cessation Phase Nicotine Patch + Nicotine Mini-Lozenge
The combination of Cessation Phase Nicotine Patch and Nicotine Mini-Lozenge is a smoking cessation therapy developed by the University of Wisconsin, Madison. This dual-therapy approach aims to reduce nicotine withdrawal symptoms and cravings by providing a steady dose of nicotine through the patch and additional doses via lozenges as needed. The treatment is designed to help smokers gradually reduce their dependence on cigarettes. While there is no FDA label, the therapy has shown promise in clinical trials and is being evaluated for broader use. Common side effects include nausea, headache, and dizziness, which are generally mild to moderate in severity.
At a glance
| Generic name | Cessation Phase Nicotine Patch + Nicotine Mini-Lozenge |
|---|---|
| Also known as | Cessation Phase Combination NRT |
| Sponsor | University of Wisconsin, Madison |
| Drug class | Nicotine replacement therapy (NRT) |
| Target | Nicotinic acetylcholine receptors |
| Modality | Small molecule |
| Therapeutic area | Hematology |
| Phase | FDA-approved |
Approved indications
Pipeline indications
Common side effects
Key clinical trials
- Varenicline for Smoking Reduction in Veterans Not Ready To Quit (PHASE4)
- A Comparative Effectiveness RCT of Optimized Cessation Treatments (PHASE4)
- The Long-Term Quitting (Smoking Cessation) Study (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: